ABSTRACT
Mpox virus (MPXV) caused a multi-country outbreak in non-endemic areas in 2022. The Modified Vaccinia Ankara (MVA)-based vaccine was used as prophylaxis, but its effectiveness remains poorly characterized. Here, we developed two assays for quantification of neutralizing antibodies (NAbs), using MVA-GFP or a recently isolated MPXV. We measured NAb levels in 470 sera from control, MPXV-infected or MVA-vaccinated individuals. Various levels of MVA NAbs were detected after infection, historic smallpox or MVA vaccination. MPXV was barely sensitive to neutralization. Addition of complement enhanced detection of responsive individuals and NAb levels. Anti-MVA and -MPXV NAbs were observed in 94% and 82% of infected individuals, respectively, and 92% and 56% of MVA vaccinees, respectively. NAb titers were higher in individuals born before 1980, highlighting the impact of historic smallpox vaccination on humoral immunity. Altogether, our results indicate that MPXV neutralization is complement-dependent and help uncover the mechanisms underlying vaccine effectiveness.
SUMMARY In 2022, mpox virus (MPXV) caused an unprecedented pandemic outbreak in non-endemic areas. The efficacy of currently available third generation MVA-based vaccines and the nature of the humoral response generated after MPXV infection remain poorly characterized. We established cell-based assays to measure neutralizing antibodies (NAbs) targeting MVA or MPXV. We analyzed 470 sera and detected robust levels of MVA NAbs after infection, historic smallpox vaccination or administration of MVA-based vaccines. Efficient MPXV neutralization required addition of complement. High NAb titers were measured in ancient smallpox-vaccinated MPXV-infected patients, suggesting a potential cross-protection mediated by hybrid immunity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Healthy donors: this study was approved by the ethical committee Comite de Protection des Personnes Ile de France III (CPP File Am844863765), on February 19, 2020 and the cohort is registered with ClinicalTrials.gov (NCT04325646).
MPXV infected patients: the study protocol was approved by the regional investigational review board CPP Ile de France VII and IX with approval reference 10023.
IMVANEX vaccinees: this study was approved by the Comite de Protection des Personnes Est II ethical committee under the reference 2022A0017736 (NCT NCT05315583).
MVAHIV recipients: the protocol was approved by an ethics committee Comite de Protection des Personnes Ile de France V, Paris, France and the competent French health authority (Agence Nationale de Securite du Medicament et des Produits de Sante) and was conducted in accordance with the declaration of Helsinki. All volunteers provided written and signed informed consent for the trial. The trial was registered with ClinicalTrials.gov (NCT02038842) and EudraCT (201200245617).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
